{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:12:12Z","timestamp":1793747532813,"version":"4.6.1"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/ico.0b013e3182542613","type":"journal-article","created":{"date-parts":[[2012,6,5]],"date-time":"2012-06-05T15:47:18Z","timestamp":1338911238000},"page":"435-444","source":"Crossref","is-referenced-by-count":45,"title":["Vascular Endothelial Growth Factor Inhibitors for Treatment of Corneal Neovascularization"],"prefix":"10.1097","volume":"32","author":[{"given":"Miltiadis","family":"Papathanassiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Theodoropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Analitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Tzonou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis G.","family":"Theodossiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210204","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":". Corneal neovascularization.","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R2-13-20210204","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: an epidemiologic review.","volume":"43","author":"Lee","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"R3-13-20210204","first-page":"264","article-title":"Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).","volume":"104","author":"Azar","year":"2006","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R4-13-20210204","first-page":"2485","article-title":"Loss and restoration of immune privilege in eyes with corneal neovascularization.","volume":"37","author":"Dana","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R5-13-20210204","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1600-0420.2006.00659.x","article-title":"Ocular angiogenesis: the role of growth factors.","volume":"84","author":"Kvanta","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"R6-13-20210204","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-0420.2004.00312.x","article-title":"Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing.","volume":"82","author":"Gan","year":"2004","journal-title":"Acta Ophthalmol Scand"},{"key":"R7-13-20210204","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inamed and vascularized human corneas.","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-13-20210204","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/archopht.1983.01040010640024","article-title":". Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization.","volume":"101","author":"Phillips","year":"1983","journal-title":"Arch Ophthalmol"},{"key":"R9-13-20210204","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archopht.1992.01080150103037","article-title":"Suppression of corneal neovascularization with cyclosporine.","volume":"110","author":"Lipman","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"R10-13-20210204","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s004170050387","article-title":". Topical application of methotrexate for inhibition of corneal angiogenesis.","volume":"237","author":"Joussen","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R11-13-20210204","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1001\/archopht.1989.01070020575043","article-title":". Promotion of graft survival by photothrombotic occlusion of corneal neovascularization.","volume":"107","author":"Corrent","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"R12-13-20210204","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ajo.2007.05.028","article-title":". Photodynamic therapy with verteporn for corneal neovascularization.","volume":"144","author":"Yoon","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R13-13-20210204","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ophtha.2011.01.041","article-title":". Horizons in therapy for corneal angiogenesis.","volume":"118","author":"Maddula","year":"2011","journal-title":"Ophthalmology"},{"key":"R14-13-20210204","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00417-008-0976-3","article-title":". Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.","volume":"247","author":"Han","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R15-13-20210204","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":". Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R17-13-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2006.02.037","article-title":". Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.","volume":"142","author":"Bashshur","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R18-13-20210204","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","article-title":"Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.","volume":"26","author":"Avery","year":"2006","journal-title":"Retina"},{"key":"R19-13-20210204","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R20-13-20210204","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":". Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R21-13-20210204","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":". Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R22-13-20210204","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":". The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration report online.","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R23-13-20210204","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00417-009-1170-y","article-title":"Avastin use in high risk corneal transplantation.","volume":"247","author":"Vassileva","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R24-13-20210204","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"27","author":"Doctor","year":"2008","journal-title":"Cornea"},{"key":"R25-13-20210204","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":". The effect of topical bevacizumab on corneal neovascularization.","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"R26-13-20210204","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/ICO.0b013e31821379aa","article-title":". Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.","volume":"30","author":"Yeung","year":"2011","journal-title":"Cornea"},{"key":"R27-13-20210204","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00417-009-1101-y","article-title":". Anti-VEGF monoclonal antibody-induced regression of corneal neovascularization and inflammation in a rabbit model of herpetic stromal keratitis.","volume":"247","author":"Saravia","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R28-13-20210204","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1167\/iovs.07-1129","article-title":". Safety profile of topical VEGF neutralization at the cornea.","volume":"50","author":"Bock","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R29-13-20210204","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1167\/iovs.08-1997","article-title":". Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.","volume":"50","author":"Chen","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R30-13-20210204","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":". Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R31-13-20210204","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":". Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.","volume":"168","author":"Jo","year":"2006","journal-title":"Am J Pathol"},{"key":"R32-13-20210204","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":". Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R33-13-20210204","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/ICO.0b013e3181b1c82f","article-title":"The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.","volume":"29","author":"Kang","year":"2010","journal-title":"Cornea"},{"key":"R34-13-20210204","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1167\/iovs.09-3745","article-title":". Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival.","volume":"51","author":"Dastjerdi","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R35-13-20210204","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3341\/kjo.2010.24.4.230","article-title":"The effect of bevacizumab on corneal neovascularization in rabbits.","volume":"24","author":"Kim","year":"2010","journal-title":"Korean J Ophthalmol"},{"key":"R36-13-20210204","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/ICO.0b013e3181e458c5","article-title":". Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition.","volume":"30","author":"Chu","year":"2011","journal-title":"Cornea"},{"key":"R37-13-20210204","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/ICO.0b013e31819839f9","article-title":"Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.","volume":"28","author":"Oh","year":"2009","journal-title":"Cornea"},{"key":"R38-13-20210204","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1755-3768.2009.01585.x","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"88","author":"Zaki","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R39-13-20210204","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","article-title":". Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R40-13-20210204","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":". Subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"R41-13-20210204","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":". Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R42-13-20210204","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":". Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R43-13-20210204","first-page":"104","article-title":". Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes.","volume":"17","author":"Rocher","year":"2011","journal-title":"Mol Vis"},{"key":"R44-13-20210204","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000322061","article-title":". Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.","volume":"46","author":"Hashemian","year":"2011","journal-title":"Ophthalmic Res"},{"key":"R45-13-20210204","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1755-3768.2009.01571.x","article-title":". The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.","volume":"88","author":"Habot-Wilner","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R46-13-20210204","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1442-9071.2010.02252.x","article-title":". Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone.","volume":"38","author":"Hoffart","year":"2010","journal-title":"Clin Experiment Ophthalmol"},{"key":"R47-13-20210204","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1167\/iovs.09-4571","article-title":". The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.","volume":"51","author":"Lin","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R48-13-20210204","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ajo.2010.04.024","article-title":". Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.","volume":"150","author":"Perez-Santonja","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R49-13-20210204","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/02713680903429007","article-title":"Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.","volume":"35","author":"Avisar","year":"2010","journal-title":"Curr Eye Res"},{"key":"R50-13-20210204","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1442-9071.2009.02112.x","article-title":". Effect of bevacizumab on corneal neovascularization in experimental rabbit model.","volume":"37","author":"Ahmed","year":"2009","journal-title":"Clin Experiment Ophthalmol"},{"key":"R51-13-20210204","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000224783","article-title":". Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.","volume":"42","author":"Hashemian","year":"2009","journal-title":"Ophthalmic Res"},{"key":"R52-13-20210204","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/02713680802607740","article-title":". The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas.","volume":"34","author":"Oh","year":"2009","journal-title":"Curr Eye Res"},{"key":"R53-13-20210204","first-page":"2326","article-title":". Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.","volume":"15","author":"Dratviman-Storobinsky","year":"2009","journal-title":"Mol Vis"},{"key":"R54-13-20210204","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","article-title":". Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.","volume":"86","author":"Yoeruek","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R55-13-20210204","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/ICO.0b013e318160d019","article-title":". Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.","volume":"27","author":"Hurmeric","year":"2008","journal-title":"Cornea"},{"key":"R56-13-20210204","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ICO.0b013e31815cf67d","article-title":". Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).","volume":"27","author":"Kim","year":"2008","journal-title":"Cornea"},{"key":"R57-13-20210204","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":". Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R58-13-20210204","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1442-9071.2007.01572.x","article-title":". Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.","volume":"35","author":"Hosseini","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"key":"R59-13-20210204","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1590\/S0001-37652007000300004","article-title":"The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea.","volume":"79","author":"Barros","year":"2007","journal-title":"An Acad Bras Cienc"},{"key":"R60-13-20210204","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":". Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R61-13-20210204","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/ICO.0b013e3181605ff9","article-title":". Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline.","volume":"27","author":"Aydin","year":"2008","journal-title":"Cornea"},{"key":"R63-13-20210204","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/08820530701543024","article-title":". Intravitreal ranibizumab and bevacizumab: a review of risk.","volume":"22","author":"Dafer","year":"2007","journal-title":"Semin Ophthalmol"},{"key":"R64-13-20210204","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/bjo.2006.098426","article-title":"Vascular endothelial growth factor biology: clinical implications for ocular treatments.","volume":"90","author":"Bhisitkul","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R65-13-20210204","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/archopht.124.10.1478","article-title":"What we dont know about avastin might hurt us.","volume":"124","author":"Gillies","year":"2006","journal-title":"Arch Ophthalmol"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0b013e3182542613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:34:02Z","timestamp":1621884842000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201304000-00013"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e3182542613","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}